Nifty
Sensex
:
:
23412.60
74608.98
33.05 (0.14%)
49.74 (0.07%)

Pharmaceuticals & Drugs - Domestic

Rating :
71/99

BSE: 506820 | NSE: ASTRAZEN

8376.00
13-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  8399.5
  •  8439.5
  •  8231.5
  •  8320.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5586
  •  46618121.5
  •  10691
  •  7551.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 20,930.50
  • 103.39
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,530.56
  • 0.38%
  • 24.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.13%
  • 13.88%
  • FII
  • DII
  • Others
  • 2.78%
  • 5.72%
  • 1.49%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.78
  • 16.10
  • 19.61

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 31.50
  • 13.39
  • 8.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 36.22
  • 4.40
  • 5.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 108.28
  • 106.68
  • 109.41

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.09
  • 20.57
  • 23.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 63.45
  • 63.53
  • 66.23

Earnings Forecasts:

(Updated: 09-05-2026)
Description
2024
2025
2026
2027
Adj EPS
46.3
P/E Ratio
188.00
Revenue
1716.29
EBITDA
253.97
Net Income
115.74
ROA
8.92
P/B Ratio
28.25
ROE
15.62
FCFF
94.05
FCFF Yield
0.46
Net Debt
-500.97
BVPS
308.14

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • AstraZeneca Pharma gets nod to import, market Acalabrutinib tablets 100 mg
    13th Apr 2026, 10:08 AM

    The company has received permission from the Central Drugs Standard Control Organisation

    Read More
  • AstraZeneca Pharma gets nod to import, market Durvalumab Solution
    17th Mar 2026, 18:20 PM

    Through this approval, Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy

    Read More
  • AstraZeneca Pharma gets CDSCO nod to import Durvalumab Solution
    10th Feb 2026, 12:23 PM

    The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India for the specified additional indication

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.